<div class="table-wrap table anchored whole_rhythm" id="Tab2">
<h3>Table 2</h3>
<!--caption a7--><div class="caption"><p id="__p14">Adverse events</p></div>
<div data-largeobj="" data-largeobj-link-rid="largeobj_idm139649444467392" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table">
<thead>
<tr>
<th rowspan="2" colspan="1">Event</th>
<th colspan="2" rowspan="1">Participants with a history of CABG</th>
<th colspan="2" rowspan="1">Participants without a history of CABG</th>
</tr>
<tr>
<th rowspan="1" colspan="1">Empagliflozin (<em>n</em> = 1175)</th>
<th rowspan="1" colspan="1">Placebo (<em>n</em> = 563)</th>
<th rowspan="1" colspan="1">Empagliflozin (<em>n</em> = 3512)</th>
<th rowspan="1" colspan="1">Placebo (<em>n</em> = 1770)</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Adverse event</td>
<td rowspan="1" colspan="1">1092 (92.9)</td>
<td rowspan="1" colspan="1">532 (94.5)</td>
<td rowspan="1" colspan="1">3138 (89.4)</td>
<td rowspan="1" colspan="1">1607 (90.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Serious adverse event<sup>a</sup>
</td>
<td rowspan="1" colspan="1">490 (41.7)</td>
<td rowspan="1" colspan="1">286 (50.8)</td>
<td rowspan="1" colspan="1">1299 (37.0)</td>
<td rowspan="1" colspan="1">702 (39.7)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Adverse event leading to discontinuation of study drug</td>
<td rowspan="1" colspan="1">215 (18.3)</td>
<td rowspan="1" colspan="1">122 (21.7)</td>
<td rowspan="1" colspan="1">598 (17.0)</td>
<td rowspan="1" colspan="1">331 (18.7)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Confirmed hypoglycaemic adverse event<sup>b</sup>
</td>
<td rowspan="1" colspan="1">409 (34.8)</td>
<td rowspan="1" colspan="1">208 (36.9)</td>
<td rowspan="1" colspan="1">894 (25.5)</td>
<td rowspan="1" colspan="1">442 (25.0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">  Requiring assistance</td>
<td rowspan="1" colspan="1">23 (2.0)</td>
<td rowspan="1" colspan="1">11 (2.0)</td>
<td rowspan="1" colspan="1">40 (1.1)</td>
<td rowspan="1" colspan="1">25 (1.4)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Adverse event consistent with urinary tract infection<sup>c</sup>
</td>
<td rowspan="1" colspan="1">187 (15.9)</td>
<td rowspan="1" colspan="1">78 (13.9)</td>
<td rowspan="1" colspan="1">655 (18.7)</td>
<td rowspan="1" colspan="1">345 (19.5)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Adverse event consistent with genital infection<sup>d</sup>
</td>
<td rowspan="1" colspan="1">91 (7.7)</td>
<td rowspan="1" colspan="1">12 (2.1)</td>
<td rowspan="1" colspan="1">210 (6.0)</td>
<td rowspan="1" colspan="1">30 (1.7)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Adverse event consistent with volume depletion<sup>e</sup>
</td>
<td rowspan="1" colspan="1">80 (6.8)</td>
<td rowspan="1" colspan="1">36 (6.4)</td>
<td rowspan="1" colspan="1">159 (4.5)</td>
<td rowspan="1" colspan="1">79 (4.5)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Acute renal failure<sup>f</sup>
</td>
<td rowspan="1" colspan="1">68 (5.8)</td>
<td rowspan="1" colspan="1">62 (11.0)</td>
<td rowspan="1" colspan="1">178 (5.1)</td>
<td rowspan="1" colspan="1">93 (5.3)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">  Acute kidney injury</td>
<td rowspan="1" colspan="1">14 (1.2)</td>
<td rowspan="1" colspan="1">21 (3.7)</td>
<td rowspan="1" colspan="1">31 (0.9)</td>
<td rowspan="1" colspan="1">16 (0.9)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Thromboembolic event<sup>f</sup>
</td>
<td rowspan="1" colspan="1">9 (0.8)</td>
<td rowspan="1" colspan="1">6 (1.1)</td>
<td rowspan="1" colspan="1">21 (0.6)</td>
<td rowspan="1" colspan="1">14 (0.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Bone fracture<sup>g</sup>
</td>
<td rowspan="1" colspan="1">49 (4.2)</td>
<td rowspan="1" colspan="1">24 (4.3)</td>
<td rowspan="1" colspan="1">130 (3.7)</td>
<td rowspan="1" colspan="1">67 (3.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Lower limb amputation<sup>h</sup>
</td>
<td rowspan="1" colspan="1">27 (2.3)</td>
<td rowspan="1" colspan="1">14 (2.5)</td>
<td rowspan="1" colspan="1">61 (1.7)</td>
<td rowspan="1" colspan="1">29 (1.6)</td>
</tr>
</tbody>
</table></div>
<div id="largeobj_idm139649444467392" class="largeobj-link align_right" style="display: none"><a target="object" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061159/table/Tab2/?report=objectonly">Open in a separate window</a></div>
<div class="tblwrap-foot">
<p id="__p15">Data are <em>n</em>
 (%) of participants treated with ≥1 dose of study drug in whom ≥1 such 
adverse event was reported. Participants can be included in ≥1 category.
 Events that occurred during treatment or ≤7 days after the last 
dose of study drug are presented</p>
<p id="__p16"><sup>a</sup>Defined as
 an adverse event that resulted in death, was immediately 
life-threatening, resulted in persistent or marked 
disability/incapacity, required or prolonged participant 
hospitalisation, was a congenital anomaly/birth defect or was deemed 
serious for any other reason</p>
<p id="__p17"><sup>b</sup>Plasma glucose ≤3.39 mmol/l and/or requiring assistance</p>
<p id="__p18"><sup>c</sup>Based on 79 Medical Dictionary for Regulatory Activities (MedDRA) preferred terms</p>
<p id="__p19"><sup>d</sup>Based on 88 MedDRA preferred terms</p>
<p id="__p20"><sup>e</sup>Based on eight MedDRA preferred terms</p>
<p id="__p21"><sup>f</sup>Based on one standardised MedDRA query</p>
<p id="__p22"><sup>g</sup>Based on 62 MedDRA preferred terms</p>
<p id="__p23"><sup>h</sup>Identified
 from events reported as adverse events, those reported as a ‘medical 
procedure’ in electronic case report forms or in investigator comments 
describing adverse events, and via a systematic search of serious 
adverse event narratives</p>
</div>
</div>
